Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Stock Information for Reviva Pharmaceuticals Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Reviva to Participate in Upcoming Investor Conferences in May 2025
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights
Reviva to Participate in the A.G.P. Healthcare Company Showcase
Reviva to Participate in the Citizens Life Sciences Conference
Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.